Mara Aspinall was named executive chairman of the Lifeprint Group's board of directors. Aspinall currently is CEO of the consulting firm Health Catalysts. She was previously the president and CEO of Roche's Ventana Medical Systems. She also spent more than a decade at Genzyme, where she held various leadership roles, including president of Genzyme Genetics and Genzyme Pharmaceuticals.
The appointment was announced by GenePeeks, a firm held by Lifeprint, which uses next-generation sequencing to help parents assess the risk of inherited diseases for their future children.